Stifel analyst Paul Matteis reiterated a Buy rating and $17.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).The analyst comments ""We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE